The AI-driven pharmaceutical sector has secured another major investment. Recently, Boston-based Alloy Therapeutics announced the completion of a $40 million Series E financing round. This latest funding values the company at $1 billion. Participants in the round included several prominent institutions such as 8VC, JIC Venture Growth Investments, and Echo Capital. Notably, existing shareholders, including Thiel Capital and Founders Fund, both associated with Peter Thiel, as well as Mubadala Capital and Alexandria Venture Investments, also participated in this round.
The newly acquired capital will be primarily allocated towards several key initiatives: upgrading the AI/ML drug discovery engine and data infrastructure to enhance artificial intelligence and machine learning capabilities; building a data infrastructure that connects the entire development workflow; deepening the capabilities of its three core platforms focused on antibodies, genetic medicines, and cell therapies; and expanding preclinical and clinical development services.
Founded in 2017 by Errik Anderson, who brings years of experience in the biotechnology industry and involvement in several successful startups, Alloy initially concentrated on antibody discovery. The company has since broadened its scope to include bispecific antibodies, genetic medicines, and cell therapies. By integrating AI-driven models, wet-lab operations, and real-world data, Alloy is positioning itself as a comprehensive service platform designed to accelerate timelines and reduce costs in drug development.
The founder stated that the company is focused on becoming foundational infrastructure for pharmaceutical R&D. "Alloy is building an infrastructure layer that connects discovery, development, and data across the global biopharma industry. Our collaborative model enables partners to remain at the forefront without needing to build all capabilities internally," he explained.
To date, Alloy has established partnerships with over 200 collaborators. These collaborations have yielded more than 100 licensed therapeutic programs. Among these, 22 have entered clinical development stages, with two currently in Phase 3 trials.
In recent years, Alloy has secured several significant business development deals with multinational pharmaceutical leaders. On April 6, the company entered into a multi-target collaboration with Biogen to develop drugs for central nervous system diseases based on its ASO platform. In February 2025, Alloy announced a strategic partnership with Pfizer to jointly develop a new platform for specific and effective antibodies. In January 2025, Alloy partnered with Sanofi SA to co-develop a novel antisense oligonucleotide (ASO) therapy, a deal that included a $27.5 million upfront payment and potential milestone payments and royalties totaling up to $400 million.
These collaborations underscore Alloy's potential across multiple platforms, spanning antibodies, bispecific antibodies, genetic medicines, and cell therapies. As pharmaceutical companies increasingly invest in AI-driven drug discovery, Alloy is accelerating its global expansion. The company reports that its business and partnerships extend across the United States, Japan, the Middle East, and other emerging biotech hubs.